HPTN Publications

Schlusser KE, Pilcher C, Kallas EG, Santos BR, Deeks SG, Facente S, Keating SM, Busch MP, Murphy G, Welte A, Quinn T, Eshleman SH, Laeyendecker O . Comparison of cross-sectional HIV incidence assay results from dried blood spots and plasma. PLoS One. 2017, 12: e0172283

Schlusser KE, Sharma S, de la Torre P, Tambussi G, Draenert R, Pinto AN, Metcalf JA, German D, Laeyendecker O, INSIGHT START Study Group . Comparison of Self-report to Biomarkers of Recent HIV Infection: Findings from the START Trial. AIDS Behav. 2018, 22: 2277-2283

Scorgie F, Khoza N, Delany-Moretlwe S, Velloza J, Mangxilana N, Atujuna M, Chitukuta M, Matambanadzo KV, Hosek S, Makhale L, Celum C . Narrative Sexual Histories and Perceptions of Hiv Risk among Young Women Taking Prep in Southern Africa: Findings from a Novel Participatory Method. [HPTN 082]. Soc Sci Med. 2021, 270: 113600

Scott H, Vittinghoff E, Irvin R, Liu A, Nelson L, del Rio C, Magnus M, Mannheimer S, Fields S, Tieu HV, Kuo I, Shoptow S, Grinsztejn B, Sanchez J, Wakefield S, Fuchs JD, Wheeler D, Mayer KH, Koblin BA, Buchbinder S . Development and Validation of the Personalized Sexual Health Promotion (SexPro) HIV Risk Prediction Model for Men Who Have Sex with Men in the United States. AIDS Behav.

Seaton KE, Huang Y, Karuna S, Heptinstall JR, Brackett C, Chiong K, Zhang L, Yates NL, Sampson M, Rudnicki E, Juraska M, deCamp AC, Edlefsen PT, Mullins JI, Williamson C, Rossenkhan R, Giorgi EE, Kenny A, Angier H, Randhawa A, Weiner JA, Rojas M, Sarzotti . Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition. EBioMedicine. 2023, 93: 104590

Seaton KE, Paez CA, Yu C, Karuna ST, Gamble T, Miner MD, Heptinstall J, Zhang L, Gao F, Yacovone M, Spiegel H, Dumond JB, Anderson M, Piwowar-Manning E, Dye B, Tindale I, Proulx-Burns L, Trahey M, Takuva S, Takalani A, Bailey VC, Kalams SA, Scott H, Mkhiz . Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A). Lancet HIV. 2025, 12: e405-e415

Seeley J, Bond V, Yang B, Floyd S, MacLeod D, Viljoen L, Phiri M, Simuyaba M, Hoddinott G, Shanaube K, Bwalya C, de Villiers L, Jennings K, Mwanza M, Schaap A, Dunbar R, Sabapathy K, Ayles H, Bock P, Hayes R, Fidler S, for the HPTN 071 Study Team . Understanding the Time Needed to Link to Care and Start ART in Seven HPTN 071 (PopART) Study Communities in Zambia and South Africa. AIDS Behav. 2019, 23: 929-946

Sekabira R, McGowan I, Yuhas K, Brand RM, Marzinke MA, Manabe YC, Frank I, Eron J, Landovitz RJ, Anton P, Cranston RD, Anderson P, Mayer KH, Amico KR, Wilkin TJ, Chege W, Kekitiinwa AR, McCauley M, Gulick RM, Hendrix CW . Higher colorectal tissue HIV infectivity in cisgender women compared with MSM before and during oral preexposure prophylaxis. AIDS. 2021, 35: 1585-1595